狄诺塞麦需要用多久？

(denosumab) is an injectable drug with the chemical name denosumab, which is approved to prevent fractures caused by cancer that has spread to bones, not to prevent or delay the spread of cancer. Today we will learn more about how long denosumab should be used?

Denosumab (denosumab) injection dose - 120mg/time; injection cycle - 4 weeks/time; injection method - subcutaneous injection; injection duration - at least 6 months;

Auxiliary matters: Please supplement calcium and vitamin D if necessary to prevent hypocalcemia; global clinical data of denosumab (denosumab), clinical results show that compared with zoledronic acid, denosumab effectively delays the incidence of first bone metastasis: lung cancer and other solid tumors - denosumab compared with zoledronic acid 20.5 months vs 16.3 months; prostate cancer - denosumab compared with zoledronic acid 20.7 months vs 17.1 months.

Denosumab (denosumab) is seen as one of the most important growth drivers for Amgen, the world's largest biotech company. Denosumab has a high affinity with RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women. The effect of denosumab on bone reconstruction can be evaluated by measuring some bone renewal markers, such as the bone resorption marker N-telopeptide, the bone formation marker bone-specific alkaline phosphatase, etc.

Amgen said denosumab (denosumab) will be able to treat 50,000 men in the United States whose disease has progressed to this stage. FDA reviewers said it's unclear whether the length of time the cancer lasts without spreading is "an appropriate measure of clinical benefit," especially since denosumab did not help men live longer or slow the growth of prostate cancer.

Studies in multiple countries have demonstrated that subcutaneous injection of denosumab every 6 months can treat postmenopausal osteoporosis in women who are at increased risk of fracture or are at high risk of fracture. Research by New Zealand scholars has found that denosumab (denosumab) is an important means of treating postmenopausal women with osteoporosis and increased risk of fracture or high risk of fracture, including female patients who are at increased risk of fracture because they are unable to undergo other treatments.

The above is the usage content of (denosumab), I hope it can help you!